All In Biotech

Drug Trial Radar · NCT07850739

Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)

A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Mar 16, 2028

Study completion May 11, 2028

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the efficacy of different dose levels of NBIP-01435 on reducing elevated androstenedione (A4) levels in adults with classic CAH.

Conditions

  • Congenital Adrenal Hyperplasia

Interventions

  • NBIP-01435Drug

    NBIP-01435 will be administered per schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in A4 Level at Week 8Time frame: Baseline, Week 8

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.